A carregar...
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of this study was to assess factors predictive for effi...
Na minha lista:
| Publicado no: | J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ivyspring International Publisher
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5370494/ https://ncbi.nlm.nih.gov/pubmed/28367230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.17644 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|